GLP-1 Users Drink Less Per Occasion, Pressuring US Spirits
Clinical evidence that GLP-1 drugs reduce alcohol cravings per drinking session threatens the profitability of restaurant beverage programs and habitual spirits categories.
GLP-1 weight-loss medications are altering American drinking habits in a way that directly threatens beverage margins in the restaurant and spirits sectors. Clinical trials indicate that while users do not necessarily stop drinking altogether, they consume fewer drinks on the occasions when they do. With 11% of U.S. adults currently using these drugs, up from 3% in 2024, the behavioral shift carries commercial weight.
For bars and restaurants, the financial risk is not empty tables but smaller checks. “The second drink is where we see the biggest behavioral change,” said Christa Cotton, CEO of New Orleans-based El Guapo. “Guests may still want to participate, but they do not always want another alcoholic drink.”
Washington, D.C., real estate agent Meg Johnston, who takes semaglutide, echoed this experience. “Alcohol just doesn’t sound as appetizing,” she said, noting her tolerance had fallen.
The spirits industry has historically relied on premiumization to offset declining volumes, arguing consumers will pay more for a higher-quality drink. The math does not necessarily hold when a customer drops from two standard cocktails to one premium pour. A more expensive first drink rarely generates the same revenue as two, while also eliminating the opportunity to sell a different spirit in the second round.
The shift arrives as broader economic pressures compound the challenge. U.S. spirits supplier sales fell 2.2% to $36.4 billion in 2025, with vodka dropping 3% and tequila and mezcal falling 4.1%, according to the Distilled Spirits Council. A May 2026 Deloitte report found four in ten U.S. consumers are value seekers, planning to cut alcohol spending at bars by more than half. The report identifies GLP-1 drugs as one influence among several driving this value consciousness.
Categories reliant on routine, repeated pours appear most exposed to the GLP-1 effect. A large randomized trial in The Lancet found semaglutide produced greater reductions in drinks per drinking day and cravings compared to a placebo. Meanwhile, premixed and ready-to-drink cocktails surged 16.4% to $3.8 billion in 2025, benefiting from controlled portions and lower-alcohol formats. For investors and operators, the data suggests drinking by default is disappearing, taking the guaranteed second round with it.
